The cost-effectiveness of cemiplimab plus chemotherapy as the first-line treatment for advanced non-small cell lung cancer

• Autors principals: Tingting Lu (Autor), Yufan Huang (Autor), Zhongjie Cai (Autor), Wangchun Lin (Autor), Xiaoxiao Chen (Autor), Ruijia Chen (Autor), Yingying Hu (Autor)
• Format: Llibre
• Publicat: Frontiers Media S.A., 2023-07-01T00:00:00Z.
• Matèries: article
• Accés en línia: Connect to this object online.

Background: The EMPOWER-LUNG 3 clinical trial has shown that cemiplimab plus chemotherapy (CCT) significantly extended overall survival (OS) and progression-free survival (PFS) for patients with advanced non-small cell cancer (NSCLC) compared to placebo plus chemotherapy (PCT). However, the cost-eff...